Meeting Overview
Refer to Accreditation Tab
Registration for this program is now closed. However, you can still register for Diabetes & Cardiometabolic Disease: Overcoming a Southern Epidemic in other southeast cities.
Despite advances in prevention, diagnosis, and treatment, diabetes and cardiometabolic disease have risen to epidemic proportions, particularly in the southeastern part of the United States. While challenging, it can be prevented and effectively managed.
Diabetes & Cardiometabolic Disease: Overcoming a Southern Epidemic, presented by Pri-Med, is a new, one-day continuing medical education program that will provide you unique, evidence-based performance improvement tools as well as case-based presentations and practical insights to help you improve patient outcomes. At this CME program, You’ll get answers to your most pertinent questions about:
- Practical solutions for the control of hyperglycemia
- How to advance therapies to achieve target goals
- Insulin use in diabetes management
- How to assess and manage cardiometabolic risk/disease
- Translating novel and emerging therapies into better patient care
Admission is complimentary
Earn up to 8.75 AMA PRA Category 1 Credits™, 8.75 AANP contact hours, or 8.75 ACPE contact hours by attending this free CME meeting in Memphis.
Have any ideas on how Pri-Med can improve your continuing medical education experience? Email us; we’d love to hear what you think.
*Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
COURSE DIRECTOR |
 |
James Gavin III, MD, PhD
CEO/Chief Medical Officer
Healing Our Village, Inc.
Clinical Professor of Medicine
Emory University
School of Medicine
Atlanta, GA |
Educational Grants
To date, the following organizations have provided educational grants in support of this Pri-Med activity:
Abbott,
Amylin Pharmaceuticals, Inc.,
Daiichi Sankyo, Inc.,
Novo Nordisk Inc.,
and Vivus.